|
|
Vaccine Detail
|
Recombinant Human Papillomavirus Nonavalent Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Human Papillomavirus Nonavalent Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007063
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- L1
gene engineering:
- Type: Recombinant protein preparation
- Description: (Van et al., 2016)
- Detailed Gene Information: Click Here.
- TPBG
gene engineering:
- Description: This is for Cervical Cancer. A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers (NCIT_C119664).
|
| Host Response |
|
|
| References |
NCIT_C119664: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119664]
Tykodi and Thompson, 2008: Tykodi SS, Thompson JA. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert opinion on biological therapy. 2008; 8(12); 1947-1953. [PubMed: 18990081].
Van et al., 2016: Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine. 2016; 34(6); 757-761. [PubMed: 26772631].
|
|
